• HOME
• BIOMOLE
  
  • Certifications
  • Articles
• PRODUCT
  • KIT
  • MIX
• SERVICES
  • Reagents
    
• CONTACT

CYP3A5 PCR real time 

Discrimination assay of CYP3A5*3 polymorphism           cod. BM-042

Principle of the test: Discrimination of CYP3A5*3 polymorphism

Technology: Real Time PCR

Gene Target: CYP3A5 gene

Specimen: DNA

Reporting Units: Genotype

Number of tests: 25 tests BM-042

Kit storage: -20°C

Necessary equipment: CFX96 DetectionSystem

Status: Ready to use

CYP3A5 PCR real time   cod. BM-042

Discrimination assay of CYP3A5*3 polymorphism

·      CYP3A5 PCR real time complete kit 25 tests BM-042

The human CYPs include 3 subfamilies, CYP1, CYP2, and CYP3, of which the CYP3A subfamily is the most common. The CYP3A subfamily is involved in tacrolimus metabolism. CYP3A4 and CYP3A5 are the most abundant and important enzymes in the CYP3A subfamily. They are strongly associated with the first-pass clearance of tacrolimus. Tacrolimus is a powerful immunosuppressant with a macrolide structure isolated from soil actinomycetes. It is one of the calcineurin inhibitors, which can inhibit activation and proliferation of T lymphocytes and indirectly affect B lymphocytes and antibody production. It was reported that the intrinsic clearance rate of tacrolimus by CYP3A5 was found to be higher than that of CYP3A4. The major single-nucleotide genetic polymorphism in CYP3A5 is the variable shear at intron 3 of CYP3A5 at site 6986 (CYP3A5 6986A>G, rs776746). When the nucleotide at site 6986 is G (CYP3A5*3), it can form an implicit receptor splice site. It directly leads to the appearance of the stop codon in advance, resulting in abnormal splicing of CYP3A5 mRNA and manifesting as a significant reduction or even disappearance of CYP3A5 enzyme activity. This resulted in different genotypes of CYP3A5 affecting blood concentrations of tacrolimus in patients. 

The CYP3A5 PCR real time BM-042  is a research use only (RUO) assay that can discriminate between the CYP3A5*1 ad CYP3A5*3 polymorphisms, offering the opportunity to evaluate their drug metabolism profile. 

Reference

1.     S Tuteja, RR Alloway, JA Johnson, AO. Gaber. The effect of gut metabolism on tacrolimus bioavailability in renal transplant recipients. Transplantation, 71 (2001), 1303-1307

2.     LK Kamdem, F Streit, UM Zanger, et al. Contribution of CYP3A5 to the in vitro hepatic clearance of tacrolimus. Clin Chem, 51 (2005), 1374-1381

3.     KA Birdwell, B Grady, L Choi, et al. The use of a DNA biobank linked to electronic medical records to characterize pharmacogenomic predictors of tacrolimus dose requirement in kidney transplant recipients. Pharmacogenet Genomics, 22 (2012), 32-42